“
“Two novel flavonoid glycosides, 6”’-dihydrophaseoylspinosin (1) and 6 ”,6”’-diferuloylspinosin (2), were isolated from the MeOH extract of Semen Ziziphi Spinosae, together with six known flavonoids, isovitexin-2 ”-O-beta-(6-O-E-feruloyl) glucopyranoside (3), spinosin

(4), isospinosin (5), 6000-feruloylspinosin (6), swertisin (7), and isovitexin-2 ”-O-beta-D-glucopyranoside (8). The structures of 1 and 2 were elucidated by spectroscopic methods including UV, IR, ESI-TOF-MS, 1D NMR, and 2D NMR experiments.”
“Microbial transformation of 7,8-dimethoxyflavone (1) by Mucor ramannianus produced five metabolites: 7,8-dimethoxy-4′-hydroxyflavone (2), 3′,4′-dihydroxy-7,8-dimethoxyflavone (3), 7,3′-dihydroxy-8-methoxyflavone (4), 7,4′-dihydroxy-8-methoxyflavone SN-38 clinical trial (5) and 8-methoxy-7,3′,4′-trihydroxyflavone (6). It was, however, completely converted to a single metabolite, 7-hydroxy-8-methoxyflavone (7) by Aspergillus flavus. 5-Methoxyflavone (8), when fermented with Beauveria bassiana, gave a single product, GW4869 concentration 5-methoxyflavanone (9). Conversion of 8 with Aspergillus alliaceus yielded the metabolite 4′-hydroxy-5-methoxyflavone (10). The structures of the compounds 2-7, 9 and 10 were established by spectroscopic

methods.”
“We clarified the impact of omentectomy for advanced gastric cancer on patient survival from the surgical results of a high-volume center in Japan.

Patients who received curative gastrectomy were divided into two groups based on whether they underwent omentectomy. The propensity score-matching method was used to assemble a well-balanced cohort, and relapse-free SRT2104 inhibitor survival and the pattern of recurrence were compared.

For this study, 330 patients who fulfilled the inclusion criteria participated and were divided into two groups: group

R, patients who received omentectomy, and group P, patients who received omentum-preserving gastrectomy. After performing score-matching, 196 patients were selected. The 3- and 5-year relapse-free survival rates were 72.9 % (95 % confidence interval, 64.1-81.7) and 66.2 % (56.6-75.8 %) in group R, and 76.7 % (67.9-81.2) and 67.3 % (55.1-79.5) in group P, which were not significantly different (P = 0.750). Regarding sites of relapses, no differences were observed between the groups (P = 0.863).

In this series, omentum-preserving gastrectomy for advanced gastric cancer did not increase the peritoneal relapse rate or affect patient survival compared to conventional gastrectomy. The non-inferiority of the omission of omentectomy should be evaluated by a randomized controlled trial.